NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology. The…

NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights. “In 2023, we demonstrated our continued commitment to transforming mental…

atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC, recently announced the encouraging findings from a study conducted by its investee, Beckley Psytech, on a pioneering DMT formulation, BPL-003, for individuals struggling with treatment-resistant depression. During this open-label Phase 2a investigation, a select group of patients received a single dose of BPL-003. This novel, synthetic formulation…

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Dr Srinivas Rao discusses the company’s development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive’s Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component in ayahuasca, known for its short-duration psychedelic effects. The innovation lies in its delivery method, an oral transmucosal…